American Shared Hospital Services Dossier
Qualitative Analysis
Business overview
American Shared Hospital Services (NYSE American: AMS) is a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services. Founded in 1980 and headquartered in San Francisco, California, the company operates primarily through two segments: Leasing and Direct Patient Service. Under its Leasing segment, AMS leases state-of-the-art medical equipment, such as Gamma Knife systems and Proton Beam Radiation Therapy (PBRT) systems, to hospitals and medical centers. The Direct Patient Service segment comprises facilities where AMS contracts directly with patients, including radiation therapy centers in Rhode Island and Puebla, Mexico.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Strategically shifting the business model from a traditional medical equipment leasing provider to an owner and operator of direct patient care facilities to capture higher-value revenue streams.
Expected impact: Direct patient care services grew to represent over 60% of total revenues, driving top-line growth despite legacy lease expirations.
Expanding clinical operations in Rhode Island by leveraging Certificate of Need (CON) approvals to build new treatment centers in Bristol and Johnston.
Expected impact: Establishes the 4th and 5th planned treatment centers in the state, strengthening partnerships with local health systems.
Expanding the company's international footprint in Latin America through joint ventures and equipment upgrades in Mexico, Peru, and Ecuador.
Expected impact: Increases international procedure volumes and diversifies geographic revenue streams.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquired a 60% majority equity interest out of the Chapter 11 bankruptcy estate of GenesisCare USA, Inc. to expand the company's owned and operated radiation oncology footprint in the United States.
Financial impact: Expected to add $9 million to $10 million in annual revenue and generated a $3.8 million bargain purchase gain in fiscal 2024.
Strategic Partnerships
Secures a seven-year extension of the long-standing proton therapy lease agreement through April 2033, providing long-term revenue visibility and stabilizing facility utilization.
Terms: Lease payments are tied to a technical component collection percentage, which is scheduled to decrease during certain 12-month periods. Includes an option for Orlando Health to purchase the equipment at the end of the lease.
AMS holds a preferred stock investment in Mevion to secure access to single-room proton therapy systems (MEVION S250) for its clinical development pipeline.
Terms: Historical equity investment representing approximately 1% ownership of Mevion.